Centure capital firm General Catalyst led the growth financing round via its Customer Value Fund, the two announced July 30. 

IAM indicates that negations with the med tech giant have remained stagnant for months, with the first comprehensive economic proposal from GE not being submitted until July.

The Luskin Orthopaedic Institute for Children recently broke ground on the project, which includes the installation of a 3T Siemens MRI system designed to deliver advanced imaging with CT-like diagnostic detail. 

The team hopes the technique could provide an objective way to identify clinical concerns earlier by assessing sodium buildup in affected tissues before severe swelling develops.

Currently, projectile incidents that occur within MRI suites are classified as “use errors.” This definition excludes such events from OEM reporting requirements.

Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback. 

Axana is designed to bring point-of-care stroke diagnosis to emergency departments and other acute care settings.

The research comes as popularity of weight loss medications has intensified in recent years, prompting concern about the loss of muscle mass among some GLP-1 users.  

The technique analyzes standard pre-contrast cardiac MRIs to produce “virtual contrast” images resembling enhanced ones.  

This can be achieved without sacrificing image quality and could offer providers the same diagnostic accuracy as full-length scans that take between 15 and 45 minutes.